StockNews.AI
PEPG
StockNews.AI
43 days

PepGen Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - PEPG

1. PepGen faces a class action lawsuit for misleading statements. 2. Allegations claim PGN-EDO51 is less effective and safe than claimed. 3. CONNECT2 study may halt due to safety and efficacy concerns. 4. Shareholders need to register by August 8, 2025, for recovery. 5. The law firm emphasizes protection against fraudulent corporate practices.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The lawsuit indicates serious concerns over PEPG's lead product's viability, significantly damaging investor confidence.

How important is it?

The allegations of misleading statements could lead to financial losses for shareholders, impacting stock price and market sentiment.

Why Long Term?

Pending developments and outcomes from the lawsuit can affect PEPG's long-term market perception and valuation.

Related Companies

NEW YORK, July 7, 2025

/PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ: PEPG).

Shareholders who purchased shares of PEPG during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/pepgen-inc-loss-submission-form/?id=155412&from=4

CLASS PERIOD:

March 7, 2024 to March 3, 2025

ALLEGATIONS:

The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that:

  • (i) the Company's lead product candidate, PGN-EDO51, was less effective and safe than defendants had led investors to believe;
  • (ii) phase two, CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration ("FDA") approval;
  • (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51's clinical, regulatory, and commercial prospects were overstated;
  • (iv) as a result, defendants' public statements were materially false and misleading at all relevant times.

DEADLINE:

August 8, 2025. Shareholders should not delay in registering for this class action. Register your information here:

https://securitiesclasslaw.com/securities/pepgen-inc-loss-submission-form/?id=155412&from=4

NEXT STEPS FOR SHAREHOLDERS:

Once you register as a shareholder who purchased shares of PEPG during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is August 8, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM?

The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

SOURCE The Gross Law Firm

Related News